New XARELTO® (rivaroxaban) Data at ESC Congress 2017 Includes Late-Breaking Results from Landmark Phase 3 COMPASS Study
Cleveland 19,
SOURCE Janssen Research
SOURCE Janssen Research
SOURCE Janssen Research
SOURCE Janssen Research
SOURCE Janssen Research
SOURCE Janssen Research
SOURCE Janssen Research
SOURCE Janssen Research
SOURCE Janssen Research
SOURCE Janssen Research
SOURCE Janssen Research
SOURCE Janssen Research
SOURCE Janssen Research
SOURCE Janssen Research
SOURCE Janssen Research
SOURCE Janssen Research
SOURCE Janssen Research
SOURCE Janssen Research
SOURCE Janssen Research
SOURCE Janssen Research
SOURCE Janssen Research
SOURCE Janssen Research
SOURCE Janssen Research
SOURCE Janssen Research
Information contained on this page is provided by an independent third-party content provider.
SOURCE Janssen Research
Information contained on this page is provided by an independent third-party content provider.
TITUSVILLE, N.J., Aug. 21, 2017 /PRNewswire/ -- New data from the landmark Phase 3 COMPASS study evaluating the use of XARELTO® …
XARELTO® is the only Factor Xa inhibitor currently under investigation in patients with coronary and peripheral artery disease…
TITUSVILLE, N.J., Aug. 21, 2017 /PRNewswire/ -- New data from the landmark Phase 3 COMPASS study evaluating the use of XARELTO® …
Editor’s Note: Cardiology Today is celebrating its 20th anniversary in 2017. We are reaching out to experts in cardiology for…
About 6.5 million U.S. adults have HF, according to the most recent report from the American Heart Association.
A new study further highlights the importance of a healthy heart. Researchers have concluded that middle-aged adults with no…
SOURCE American Regent - HEART-FID is one of the largest studies to look at intravenous (IV) ferric carboxymaltose (FCM) iron…
SOURCE American Regent - HEART-FID is one of the largest studies to look at intravenous (IV) ferric carboxymaltose (FCM) iron…
SOURCE American Regent - HEART-FID is one of the largest studies to look at intravenous (IV) ferric carboxymaltose (FCM) iron…
SOURCE American Regent - HEART-FID is one of the largest studies to look at intravenous (IV) ferric carboxymaltose (FCM) iron…
SOURCE American Regent - HEART-FID is one of the largest studies to look at intravenous (IV) ferric carboxymaltose (FCM) iron…
SOURCE American Regent - HEART-FID is one of the largest studies to look at intravenous (IV) ferric carboxymaltose (FCM) iron…
SOURCE American Regent - HEART-FID is one of the largest studies to look at intravenous (IV) ferric carboxymaltose (FCM) iron…
SOURCE American Regent - HEART-FID is one of the largest studies to look at intravenous (IV) ferric carboxymaltose (FCM) iron…
SOURCE American Regent - HEART-FID is one of the largest studies to look at intravenous (IV) ferric carboxymaltose (FCM) iron…
Information contained on this page is provided by an independent third-party content provider.
SOURCE American Regent - HEART-FID is one of the largest studies to look at intravenous (IV) ferric carboxymaltose (FCM) iron…
SOURCE American Regent - HEART-FID is one of the largest studies to look at intravenous (IV) ferric carboxymaltose (FCM) iron…
In the battle to lose weight, many people switch to diet sodas. But while they cut calories they might also raise the risk of…
SOURCE American Regent - HEART-FID is one of the largest studies to look at intravenous (IV) ferric carboxymaltose (FCM) iron…
SOURCE American Regent - HEART-FID is one of the largest studies to look at intravenous (IV) ferric carboxymaltose (FCM) iron…
SOURCE American Regent - HEART-FID is one of the largest studies to look at intravenous (IV) ferric carboxymaltose (FCM) iron…
SOURCE American Regent - HEART-FID is one of the largest studies to look at intravenous (IV) ferric carboxymaltose (FCM) iron…
SOURCE American Regent - HEART-FID is one of the largest studies to look at intravenous (IV) ferric carboxymaltose (FCM) iron…
SOURCE American Regent - HEART-FID is one of the largest studies to look at intravenous (IV) ferric carboxymaltose (FCM) iron…
SOURCE American Regent - HEART-FID is one of the largest studies to look at intravenous (IV) ferric carboxymaltose (FCM) iron…
SOURCE American Regent - HEART-FID is one of the largest studies to look at intravenous (IV) ferric carboxymaltose (FCM) iron…
SOURCE American Regent - HEART-FID is one of the largest studies to look at intravenous (IV) ferric carboxymaltose (FCM) iron…
SOURCE American Regent - HEART-FID is one of the largest studies to look at intravenous (IV) ferric carboxymaltose (FCM) iron…
SOURCE American Regent - HEART-FID is one of the largest studies to look at intravenous (IV) ferric carboxymaltose (FCM) iron…
SOURCE American Regent - HEART-FID is one of the largest studies to look at intravenous (IV) ferric carboxymaltose (FCM) iron…
SOURCE American Regent - HEART-FID is one of the largest studies to look at intravenous (IV) ferric carboxymaltose (FCM) iron…
SOURCE American Regent - HEART-FID is one of the largest studies to look at intravenous (IV) ferric carboxymaltose (FCM) iron…
SOURCE American Regent - HEART-FID is one of the largest studies to look at intravenous (IV) ferric carboxymaltose (FCM) iron…
SOURCE American Regent - HEART-FID is one of the largest studies to look at intravenous (IV) ferric carboxymaltose (FCM) iron…
People with type 1 diabetes face the risk of developing a disease that can cause blindness, so treatment guidelines have long…
Information contained on this page is provided by an independent third-party content provider.
American Regent, a member of the Daiichi Sankyo Group, announced that the first patient has been enrolled into the phase 3…
American Regent, a member of the Daiichi Sankyo Group, announced that the first patient has been enrolled into the phase 3…
American Regent, a member of the Daiichi Sankyo Group, announced that the first patient has been enrolled into the phase 3…
American Regent, a member of the Daiichi Sankyo Group, announced that the first patient has been enrolled into the phase 3…
American Regent, a member of the Daiichi Sankyo Group, announced that the first patient has been enrolled into the phase 3…
American Regent, a member of the Daiichi Sankyo Group, announced that the first patient has been enrolled into the phase 3…
American Regent, a member of the Daiichi Sankyo Group, announced that the first patient has been enrolled into the phase 3…
American Regent, a member of the Daiichi Sankyo Group, announced that the first patient has been enrolled into the phase 3…
American Regent, a member of the Daiichi Sankyo Group, announced that the first patient has been enrolled into the phase 3…
American Regent, a member of the Daiichi Sankyo Group, announced that the first patient has been enrolled into the phase 3…
American Regent, a member of the Daiichi Sankyo Group, announced that the first patient has been enrolled into the phase 3…
American Regent, a member of the Daiichi Sankyo Group, announced that the first patient has been enrolled into the phase 3…
American Regent, a member of the Daiichi Sankyo Group, announced that the first patient has been enrolled into the phase 3…
American Regent, a member of the Daiichi Sankyo Group, announced that the first patient has been enrolled into the phase 3…
American Regent, a member of the Daiichi Sankyo Group, announced that the first patient has been enrolled into the phase 3…
SOURCE American Regent - HEART-FID is one of the largest studies to look at intravenous (IV) ferric carboxymaltose (FCM) iron…
- HEART-FID is one of the largest studies to look at intravenous (IV) ferric carboxymaltose (FCM) iron therapy as a treatment…
- HEART-FID is one of the largest studies to look at intravenous (IV) ferric carboxymaltose (FCM) iron therapy as a treatment…
/PRNewswire/ -- American Regent, a member of the Daiichi Sankyo Group, announced that the first patient has been enrolled into…
(GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO) (ASX:MSB) today announced that the Phase 3 trial of its allogeneic…
(GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced that the Independent Data Monitoring Committee (IDM…
(GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced that the Independent Data Monitoring Committee (IDM…
(GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO) (ASX:MSB) today announced that the Independent Data Monitoring Committee (IDM…
/PRNewswire/ -- Novartis announced today results of a new post-hoc analysis in a subgroup of patients with reduced ejection…
... EAST HANOVER N.J. March 18 2017 /PRNewswi...Entresto lowered HbA1c levels – a measure of average blood glucose lev...
Information contained on this page is provided by an independent third-party content provider.
Information contained on this page is provided by an independent third-party content provider.
Information contained on this page is provided by an independent third-party content provider.
Information contained on this page is provided by an independent third-party content provider.
Information contained on this page is provided by an independent third-party content provider.
Information contained on this page is provided by an independent third-party content provider.
Information contained on this page is provided by an independent third-party content provider.
Information contained on this page is provided by an independent third-party content provider.
Information contained on this page is provided by an independent third-party content provider.
Information contained on this page is provided by an independent third-party content provider.
Information contained on this page is provided by an independent third-party content provider.
Information contained on this page is provided by an independent third-party content provider.